Distribution, dosimetry and imaging of [195mPt]cisplatin in cancer patients

Distribution, dosimetry and imaging of [195mPt]cisplatin in cancer patients - [195mPt]cisplatin imaging

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55147

Enrollment

Registered

2022-01-28

Start date

2022-07-12

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer Non-small-cell lung carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - > 18 years of age. - Diagnosed with NSCLC. - Planned for concurrent radiotherapy with cisplatin. - At least one pulmonary tumour lesion of at least 3 cm over the longest axis.

Exclusion criteria

Exclusion criteria: - Not able to provide informed consent. - Pregnant or breastfeeding. - Previous treatment with platinum compounds. - Claustrophobia. - eGFR

Design outcomes

Primary

Measure	Time frame
- Image quality: amongst others tumour-to-background ratio and visual assessment - Dosimetry	—

Secondary

Measure	Time frame
- eGFR - Treatment outcome according to MTB/physician decision.	—

Countries

Netherlands

Outcome results